This is a working overview of thymosin beta-4 fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-11. Anything still debated is marked as such rather than presented as settled.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
| Property | Value | Notes |
|---|---|---|
| Generic designation | Synthetic thymosin beta-4 N-terminal fragment | Peptide nomenclature varies by supplier |
| Peptide length | Approximately 17 amino acid residues | Reported length sometimes differs between sources |
| N-terminal modification | Acetyl group | Affects mass and chromatographic behaviour |
| Compound class | Small synthetic peptide | Not a small-molecule drug |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Naming is inconsistent in popular media |
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
=== PIDDosome === PIDD-CC serves as a nucleating agent for the assembly of a complex with the dual adaptor protein RAIDD, which plays a pivotal role in the recruitment and activation of CASP2, potentially triggering apoptotic pathways. This assembly is widely recognized as the PIDDosome. In contrast, signaling pathways involving PIDD-C are primarily linked to the activation of NF-κB, thereby enhancing cell survival. In response to DNA damage, PIDD-C undergoes translocation to the nucleus, where it forms a complex with RIP1 and the NF-κB essential modulator (NEMO, also known as IKBKG), collectively termed the NEMO-PIDDosome. The term "PIDDosome" is commonly used to refer to a multiprotein complex that is made up of p53-induced death domain protein 1 (PIDD1), the bipartite linker protein CRADD (also known as RAIDD), and the inactive precursor of the caspase family endopeptidase, called caspase-2.
. In chromatography, the area of a peak is proportional to the number of moles (n) times some constant of proportionality (k), Area = k×n. The number of moles of compound is equal to the concentration (c) times the volume, n = cV. From these equations, the following derivation is made:
==== Financial status ==== Poverty and an individual's financial status play a critical role in the challenges of mental health. Low-income individuals and families often experience physical barriers to accessing mental health treatments, significantly increasing the chances of mental health struggles. Job insecurity, shame surrounding financial resources, and inability to seek professional help stimulate external and internal stigma. Societal norms may lead to an expectation that if financially unsuccessful, unemployment results in personal failure and negative stereotypes. Unemployed individuals may be perceived as irresponsible, unmotivated, and lazy. Psychological stress surrounding financial stability causes internalized discrimination and societal judgment. A study emphasized that using interventions and professional treatments will reduce psychological stress, normalize needing accessible health care, and decrease stigma around mental health regardless of economic background.
== Habitat == Arnebia densiflora prefers mountain areas and places with dry and sunny rocky soils. It is native to Greece and Turkey on volcanic or limestone slopes and cliffs at 750–2,600 m (2,460–8,530 ft).
Sources: en.wikipedia.org
== History == 1996 - Institut für Bioanalytik GmbH was founded by Herbert Stadler, IBA introduces Strep-tag products 1998 - Acquisition of NAPS Göttingen GmbH (Nucleic Acid Products Supply) 1999 - Biologics joint venture with GBF Braunschweig 2001 - Institut für Bioanalytik GmbH was renamed to IBA GmbH 2003 - IBA introduces Streptamer cell isolation technology 2004 - Operations segmented into Protein, Gene and Cell TAGnology business units 2007 - IBA introduces StarGate cloning system 2008 - Innovation Award for StarGate 2010 - IBA introduces Fab-Streptamer technology 2011 - Innovation Award for Streptamer cell isolation technology 2012 - IBA introduces Fab-TACS (Formerly known as T-CATCH) column based cell purification 2014 - IBA earned its ISO 9001:2008 certification for Quality Management Standard, IBA introduces Strep-Tactin XT products 2015 - 6th foreign Trade Award of Lower Saxony (Germany), IBA launches MEXi mammalian expression system 2016 - IBA introduces cell selection device FABian
This system is used in many unrelated animals: ants, bees, and wasps, termites, naked mole-rat, Damaraland mole-rat, Synalpheus regalis shrimp, certain beetles, some gall thrips and some aphids. Oxygenate blood came about in unrelated animals groups: vertebrates use iron (hemoglobin) and crustaceans and many mollusks use copper (hemocyanin). Biomineralization the secrete protective shells or carapaces made out of organically made hard materials like mineral carbonates and organic chitins came about in unrelated species all at the same time during the cambrian Explosion in: mollusks, brachiopods, arthropods, bryozoans, echinoderms, tube worms. Reef builders, a number of unrelated species of sea life build rocky like reefs: some types of bacteria make stromatolites, various sponges build skeletons of calcium carbonate, like: archaeocyath sponges, and stromatoporoid sponges, corals, some anthozoan cnidarians, bryozoans, calcareous algae and some bivalves (rudist bivalves). Magnetite for orientation, magnetically charged particles of magnetite for directional sensing have been found in unrelated species of salmon, rainbow trout, some butterflies and birds. Hydrothermal vent adaptations like the use of bacteria housed in body flesh or in special organs, to the point they no longer have mouth parts, have been found in unrelated hydrothermal vent species of mollusks and tube worms (like the giant tube worm). Lichens are partnerships of fungi and algae. Each "species" of lichen is make of different fungi and algae species, thus each has to come about independently.
Analogues of 4-HO-NiPT include 4-hydroxytryptamine (4-HT or 4-HO-T), 4-HO-MiPT (miprocin), 4-HO-DiPT (diprocin), psilocin (4-HO-DMT), norpsilocin (4-HO-NMT), 4-HO-NET, 4-HO-NPT, 4-HO-NALT, and 4-HO-NBnT, among others.
Sources: en.wikipedia.org
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.
No. Thymosin beta-4 is the full-length protein of about forty-three amino acids, while the fragment covers only its beginning. The two are related but are not interchangeable in experimental or analytical terms.
The label is a catalogue designation that became common in non-technical discussion. Scientific papers usually refer to the fragment by sequence or as a thymosin beta-4 N-terminal peptide.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.